Brought to you by 
Newron grants Meiji Seika exclusive Asian rights to safinamide; Meiji later sublicenses to Eisai
11 Apr 2017
Executive Summary
Firming up the letter of intent signed last month, Meiji Seika Pharma Co. Ltd. (the prescription pharmaceuticals division of diversified Japanese company Meiji Holdings Co. Ltd.) entered a definitive agreement with Newron Pharmaceuticals SPA (CNS-focused therapeutics) to license the latter's safinamide (NW1015).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Newron grants Meiji Seika exclusive Asian rights to safinamide; Meiji later sublicenses to Eisai
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice